FDA Approves Signos Glucose Monitor for Weight Loss

The FDA has approved Signos’ glucose monitoring system for weight management, marking a first in the digital wellness space. Signos, a startup, offers a subscription service that includes glucose sensors and an app, which uses AI to provide personalized health insights. The system pairs with Dexcom’s Stelo CGM sensor patch, already available over the counter. This approval could allow Signos’ service to be covered by HSA and FSA plans and potentially reimbursed by insurance. The app aims to help users make informed lifestyle choices, offering an alternative to pharmacological and surgical weight loss methods. This development highlights the growing role of technology in personal health management.